Table 1.

Possible Factors Influencing 5-α-Reductase Therapy

Percentage of DHT inhibition with increased testosterone Pathologic variability Variability by prostate size Epithelial/stromal ratio Lobar distribution of 5-α-reductase Time of treatment initiation Patient selection (LUTS/BOO) Other factors (eg, alpha tone) Patient compliance

LUTS, lower urinary tract symptoms; BOO, bladder outlet obstruction.